Technology Bundle ID: TAB-2725

Novel Primate T-cell Lymphotropic Viruses (HTLV, STLV) for Development of Diagnostics, Therapeutics, Research Tools, and Vaccines

Request More Info
Licensing Contact:
Co-Inventors: 
Thomas Folks (CDC), Walid Heneine (CDC), William Switzer (CDC)
Development Stage: 
Pre-Clinical (in vitro)
Development Status: 
  • Early-stage
  • In vitro data available
Institute or Center: 
CDC

CDC researchers have isolated and characterized the novel primate T-lymphotropic viruses denoted human T-lymphotropic viruses 3 and 4 (HTLV-3 and HTLV4), that are believed to have resulted from cross-species transmission at some point in the past. It has been previously established that HTLV-1 causes adult T cell leukemia and other inflammatory diseases; HTLV-2 is considered less pathogenic than HTLV-1 and has been associated with a neurologic disease similar to HTLV-1-associated myelopathy. At present, the human pathologies of HTLV-3 and HTLV-4 are yet uncharacterized, but have been identified as infecting rural Central African hunters who have much greater risk of contact with non-human primates, sometimes infected with simian T-lymphotropic viruses (STLVs). As HTLV infected individuals from rural, isolated populations have increasing contact with their urban brethren, there is increased potential for the rapid spread of new viral zoonotic-originating pathogens, much like the theorized "bushmeat" origins of HIV. There is a present and unmet need for increased surveillance, study, and preventative therapeutics directed towards mitigating the public health impact of these viruses. This CDC developed technology provides methods and tools to that end.

Applications:
  • Development of HTLV diagnostics
  • Simian/human T-cell lymphotropic virus research
  • Zoonosis surveillance
  • Vaccine design and development
Advantages:
  • Provides tremendous opportunity for phylogenetic, clinical and epidemiological investigations of HTLV and STLV
  • Facilitates monitoring of viral diversity and study of zoonotic disease transmission
  • Provides tools needed to address and mitigate a newly emergent blood-borne disease before widespread, regional/global viral dissemination occurs

Patents

PCT Application PCT/US2006/005869
Filed on 2006-02-21
US Application 60/654,484
Filed on 2005-02-21
US Pat 7,794,998

Issued 2010-09-14
US Pat 8,541,221

Issued 2013-09-24
US Pat 9,435,000

Issued 2016-09-06

Various international patents granted and pending

Publications

Switzer WM, et al.
PMID 19187529
Wolfe ND, et al.
PMID 15911757

Updated

Jan 16, 2014

Data Source: 
tts